Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 51

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 51
---
 of the Merger.

The pro forma financial statements
contained in this prospectus are presented for illustrative purposes only and may not be an indication of the Company’s financial
condition or results of operations following the completion of the Merger for several reasons. The pro forma financial statements have
been derived from the historical financial statements of Aptorum and DiamiR and adjustments and assumptions have been made regarding the
Combined Company after giving effect to the Merger. The information upon which these adjustments and assumptions have been made is preliminary,
and these kinds of adjustments and assumptions are difficult to make with accuracy. As a result, the actual financial condition and results
of operations of the Combined Company following the completion of the Merger may not be consistent with, or evident from, these pro forma
financial statements. The assumptions used in preparing the pro forma financial information may not prove to be accurate, and other factors
may affect the Combined Company’s financial condition or results of operations following the Merger. Any decline or potential decline
in the Combined Company’s financial condition or results of operations may cause significant variations in the market price of the
Combined Company’s securities.

DiamiR has never generated revenue from product sales and all of DiamiR’s product candidates are currently in the pre-commercial stage, and DiamiR may continue to incur significant losses for the foreseeable future and never generate revenue from product sales.

DiamiR is a molecular diagnostic
company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s,
Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology they developed is based on quantitative analysis
of circulating organ-enriched microRNAs in plasma. Short-term objectives of the Company include the development of Lab-Developed tests
(LDTs) in its CLIA licensed lab based on the identified miRNA expression signatures. The tests could also be used for patient screening
and stratification, as well as disease and treatment monitoring. DiamiR has devoted most of its financial resources to conducting studies
on analysis of circulating organ-enriched miRNA biomarkers and building its patent portfolio. DiamiR has not completed development of
any product candidate and has therefore not generated any revenues from product sales. DiamiR’s ability to fully develop its products
and market them successfully is depending on may factors, some of which are out of their control and many of which are described elsewhere
in this proxy statement/prospectus. Although DiamiR has received